Target intelligence / Profile preview

New York esophageal squamous cell carcinoma 1 protein (NY-ESO-1)

Target: NY-ESO-1
Molecular classification: Cancer/testis antigen (CTA), Cancer Testis Antigen Family

Overview

New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a cancer/testis antigen (CTA) with restricted expression in normal adult tissues and aberrant re-expression in various cancers. Its strong immunogenicity makes it a target for immunotherapy. It is encoded by the CTAG1B gene and elicits both humoral and cellular immune responses. The precise biological function of NY-ESO-1 remains incompletely understood, but it may be involved in cell cycle regulation, proliferation, or stem/germ cell self-renewal/differentiation.

Other names: CTAG1BCancer/testis antigen 1B

Mechanism of action

Immunotherapy strategies (vaccines, adoptive T-cell therapies) aim to elicit or enhance anti-tumor immune responses against NY-ESO-1 expressing cells.

Biological functions

Cell cycle regulation (potential)Cell proliferation (potential)Apoptosis (potential)Stem/germ cell self-renewal/differentiation (potential)Immune response

Disease associations

CancerMyxoid/round cell liposarcomaNeuroblastomaSynovial sarcomaMelanomaOvarian cancerBladder cancerEsophageal cancerHepatocellular carcinomaHead and neck cancersNon-small cell lung cancer (NSCLC)Prostate cancerBreast cancerCervical cancerGastric carcinomaLiver carcinomaHematological malignancies

Safety considerations

Potential for off-target effects in normal tissues with low-level NY-ESO-1 expression.Risk of immune-related adverse events associated with immunotherapy.

Biomarkers

NY-ESO-1 expression level in tumor tissueAntibody titers against NY-ESO-1

Beyond the preview

Go deeper on New York esophageal squamous cell carcinoma 1 protein (NY-ESO-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New York esophageal squamous cell carcinoma 1 protein (NY-ESO-1).

Explore the full profile